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ABSTRACT
Implantable Cardioverter Defibrillators (ICDs) have 
evolved from a treatment of last resort to the current 
and rapidly growing use as a first line therapeutic 
option. Early clinical trials captured what had only been 
apparent in observational studies that subsequently 
paved the way for the utilization of ICDs as secondary 
prevention in patients who had survived life-threaten-
ing arrhythmias. As a result, these randomized clinical 
trials exhibited a benefit with ICD only in high-risk 
patients with ischemic cardiomyopathy. However, recent 
studies have been able to demonstrate a significant role 
for primary prevention in selected high-risk patients 
with non-ischemic cardiomyopathy. 
INTRODUCTION
Sudden cardiac death (SCD) is among the most com-
mon causes of mortality. It is estimated that more than 
450,000 deaths are attributed to SCD primarily due to 
ventricular tachycardia (VT) or ventricular fibrillation 
(VF), with a survival rate of approximately 5 percent 
(Zheng et al., 2001; Zipes and Wellens, 1998). Although 
there has been a reduction in total cardiac mortality, the 
percentage of deaths from SCD has increased. In fact, 
SCD accounts for more deaths each year than the total 
number of deaths from AIDS, breast cancer, lung cancer, 
and stroke (Josephson et al., 2000). In addition, the risk 
of sudden death increases dramatically in patients with 
heart failure (Ellison et al., 2003). Although new medical 
therapies have helped patients with heart failure live 
longer, SCD remains a distinctly unpredictable facet of 
this chronic disease. 
In the 1970s, doctors Michael Mirowski and Morton 
Mower, motivated by the sudden death of a colleague, 
conceived and developed an implantable device that 
would detect rhythm abnormalities and deliver defibril-
lating shocks, the early ICD. They theorized that most of 
the energy required for external defibrillation wastefully 
dissipated in surrounding tissues. They believed that a 
shock delivered directly to the heart would require 
much less energy, and that a device to deliver it could be 
made small enough to be implanted in the human body. 
Mirowski implanted the first device in a human in 1980 
and in 1985, the Food and Drug Administration (FDA) 
approved the use of ICDs, (Mirowski and Mower, 1973; 
Mirowski et al., 1978; Mirowski et al., 1980). 
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Initially, attempts at preventing SCD were aimed at sup-
pression of ventricular ectopy, but it was not until the 
Cardiac Arrhythmia Suppression Trial (CAST) revealed 
that the treatment of asymptomatic ventricular prema-
ture contractions and non-sustained VT with antiarryth-
mic drugs was not only inappropriate, but also danger-
ous (Etcht et al., 1991). Over the years ICDs have become 
a first line therapeutic modality for the secondary pre-
vention of SCD and for primary prevention in selected 
patients. Recently, however, new studies have paved the 
way for more inclusive criteria for the use of ICDs as pri-
mary prevention. Since only a minority of patients survive 
an episode of SCD, identifying patients at high risk for 
SCD is crucial. 
This article reviews the early studies that initially led to 
the use of ICDs as secondary preventative measures and 
examines their indications as primary preventative mea-
sures in both ischemic and non-ischemic cardiomyopathy. 
Recent studies have examined primary and secondary 
prevention trials and the potential impact of ICDs in 
patient survival and sudden cardiac death (Ezekowitz et 
al., 2003; Lee et al., 2003; Domanski et al., 1999; Buxton 
et al., 1999). In addition, several significant primary pre-
vention trials have recently been introduced (Hohnloser 
et al., 2004; Kadish et al., 2004; Bardy et al., 2005). 
Until now, the role of ICDs in this patient population 
had remained equivocal; however, these studies have 
begun to elucidate a more significant role in this patient 
population.
 
SECONDARy pREvENTION
Initial uncontrolled studies suggested that ICDs reduced 
the rate of SCD (Fogoros et al., 1987; Tchou et al., 1988; 
Kelly et al., 1988; Fogoros et al., 1990). However, in these 
studies the delivery of a shock by the ICD was understood 
to surrogate an end point. Such an approach overes-
timated the benefit of defibrillators, as not all shocks 
are appropriate and not all arrhythmias lead to sudden 
death (Winkle et al., 1989). In addition, confidence in 
conventional antiarrhythmic therapy to prevent sud-
den death was questioned by many (Etcht et al., 1991; 
Mason, 1993). Therefore, randomized controlled trials 
(RCTs) were conducted to evaluate the true effect of 
implantable defibrillators. Secondary prevention trials 
enrolled patients with previous history of cardiac arrest 
or sustained VT and compared ICD therapy with standard 
therapy (Tables 1 and 2).
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The Cardiac Arrest Survival in Hamburg (CASH) study 
evaluated the effect of ICDs versus anti-arrhythmic 
medication (amiodarone, metoprolol, and propafenone) 
as a secondary measure in survivors of cardiac arrest 
secondary to documented ventricular arrhythmia (Kuck 
et al., 2000). The propafenone arm was discontinued 
early in the study after interim analysis revealed a 61 
percent higher mortality rate during follow up (Siebels 
et al., 1993). The study demonstrated a reduction in 
total mortality in patients receiving ICD compared to 
drug therapy (36.4 versus 44.4 percent, P=0.08) and a 
significant reduction in mortality due to SCD (13 versus 
33 percent, P=0.005). 
The Canadian Implantable Defibrillator Study (CIDS) 
trial enrolled patients with resuscitated VF, sustained 
VT, or unmonitored syncope deemed to be secondary to 
arrhythmia for treatment with ICD or with amiodarone 
(Connolly et al., 2000a). After a three-year follow-up, a 
non-significant 20 percent reduction in the risk of death 
was observed (10.2 versus 8.3 percent per year, P=0.142), 
as well as a non-significant reduction in SCD alone. 
In a follow-up study, Sheldon and his colleagues analyzed 
the outcome in order to identify subgroup of patients 
most likely to benefit from ICD therapy (Sheldon et al., 
2000). They identified age, ejection fraction (EF), and 
New York Heart Association (NYHA) class as independent 
predictors of risk, and based on these parameters, quar-
tiles of risk were constructed. Patients in the highest risk 
quartile with at least two risk factors (age greater than 
70, left ventricular EF (LVEF) of no more than 35 percent, 
and NYHA class III or IV) had a significant reduction of 
death from the ICD compared to amiodarone (14.4 ver-
sus 30 percent). 
The Antiarrhythmic Drug Versus Defibrillator (AVID) trial 
randomized patients who were resuscitated from near-
fatal VF or sustained VT to either treatment with ICD, 
or medical treatment with amiodarone. The trial was 
terminated early when a significant relative reduction in 
mortality was noted in the ICD group. As expected, the 
major effect of the ICD was to prevent arrhythmic sud-
den death (4.7 versus 10.8 percent). A follow up evalu-
ation by the AVID investigators revealed no significant 
Trial N Age Mean Follow-ups Control
   LVEF (%) (Months) Therapy
CASH 288* 58 ± 11 45 57 ± 34 Amiodarone or
     Metoprolol 
CIDS 659 64 ± 9 34 36 Amiodarone
AVID 1016 65 ± 10 32 18 ± 12 Amiodarone
TABLE 1 I SECONDARY PREVENTION TRIALS BASELINE CHARACTERISTICS
AvID = Antiarrhythmic Versus Implantable Defibrillator; CASH = Cardiac Arrest Study Hamburg; CIDS = Canadian 
Implantable Defibrillator Study; LvEF = left ventricular ejection fraction; Plus-minus values are means ± standard 
deviation. * Excludes patients assigned to Propafenone 
TABLE 2 I SECONDARY PREVENTION TRIALS EFFECT ON MORTALITY AND SCD
 Overall Mortality (%) Death Due to Sudden Cardiac Death (%)
Trial Control ICD P Control ICD P
CASH 44.4 36.4 0.08 33.0 13.0 0.005
CIDS 29.6 25.3 0.14 13.1 9.0 0.094
AVID 24.0 15.8 0.02 10.8 4.7 *
AvID = Antiarrhythmic Versus Implantable Defibrillator; CASH = Cardiac Arrest Study Hamburg; CIDS = Canadian 
Implantable Defibrillator Study; ICD = implantable cardioverter defibrillator; SCD = Sudden Cardiac Death. 
*= significant difference, but P value not available
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improvement in survival in patients treated with ICD 
therapy, with LVEF of greater than 35 percent (83.4 ver-
sus 82.7 percent at two years). However, in those with an 
LVEF between 20-34 percent, survival was significantly 
improved (Domanski et al., 1999).
In a meta-analyses Connolly and colleagues combined all 
three trials described above and revealed a significant 
28 percent relative risk reduction in all cause mortal-
ity (Connolly et al., 2000b). SCD alone decreased by 50 
percent. Furthermore, over a follow-up of six years, 
the ICD extended survival by 4.4 months. The analysis 
also confirmed previous findings; patients with EFs of 
greater than 35 percent received less benefit (P=0.011). 
Finally, patients treated with ICDs implanted before July 
1st 1991, the “epicardial era,” received significantly less 
benefit than endocardial systems. 
pRIMARy pREvENTION
Primary prevention trials enrolled participants who were 
high-risk for fatal ventricular arrhythmias. While initial 
studies focused on patients with ischemic cardiomy-
opathy, recent trials have addressed and extended the 
concentration to patients with non-ischemic cardiomy-
opathy. 
Ischemic (Tables 3 and 4)
The Multicenter Automatic Defibrillator Implantation 
Trial (MADIT) enrolled patients with a prior history of 
coronary artery disease, NYHA class I-III, EF of less than 
35 percent, a documented episode of asymptomatic 
unsustained VT, and inducible non-suppressible VT on 
Trial N Age Mean  Follow-ups Control
   LVEF (%) (Months) Therapy
MADIT  196 63  ± 9 26 27 Conventional
MADIT II 1232 64  ± 10 23 20 Conventional
CABG Patch 900 64  ± 9 27 32  ± 16 No ICD
MUSTT 704 67  ± 12 30 39 No EP-guided therapy 
DINAMIT 674 62 28 30 Placebo
TABLE 3 I  PRIMARY PREVENTION TRIALS IN PATIENTS WITH ISCHEMIC 
 CARDIOMYOPATHY 
CABG patch = Coronary Artery Bypass Graft Patch Trial; DINAMIT = Defibrillator in Acute Myocardial Infarction 
Trial LvEF = left ventricular ejection fraction; MADIT = Multicenter Automatic Defibrillator Implantation Trial; 
MUSTT = Multicenter Unsustained Tachycardia; Plus-minus values are means ± standard deviation.
 Overall Mortality (%) Death due to SCD (%)
Trial Control ICD P Control ICD P
MADIT  38.6 15.8 0.009 12.9 3.2 *
MADIT II 19.8 14.2 0.016 9.9 3.8 <0.01
CABG Patch 21.3 22.2 0.64 6.2 3.4 †
MUSTT 48.0 42.0 0.06 See Table 5
DINAMIT 17.0 18.7 0.66 8.5 3.6 0.009
TABLE 4 I  PRIMARY PREVENTION TRIALS IN PATIENTS WITH ISCHEMIC 
 CARDIOMYOPATHY AND EFFECT ON MORTALITY AND SCD
CABG patch = Coronary Artery Bypass Graft Patch Trial; DINAMIT = Defibrillator in Acute Myocardial Infarction 
Trial; ICD = implantable cardioverter defibrillator; MADIT = Multicenter Automatic Defibrillator Implantation Trial; 
MUSTT = Multicenter Unsustained Tachycardia; SCD = Sudden Cardiac Death. 
*= Significant difference, P value not available
†= Non-significant difference, P value not available
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electrophysiologic study (Moss et al., 1996). They were 
randomized to receive either an ICD or managed with 
conventional medical therapy at the discretion of indi-
vidual physicians. However, 74 percent of patients in the 
conventional treatment group received amiodarone. 
After an average follow-up of 27 months, 15 deaths 
occurred in the ICD group and 39 in the conventional 
group, for a relative reduction of 54 percent (P=0.009).
However, the limited number of patients enrolled and 
the stringent inclusion criteria limit the study’s general-
izability. Furthermore, since the study required enrolling 
patients with inducible sustained VT not responsive to 
antiarrhythmic therapy, it favored high-risk patients 
who would be less likely to be well managed with phar-
maceutical therapy. Nevertheless, examination of such 
discrepancy by the authors did not reveal any significant 
interaction. 
In addressing these criticisms, the second Multicenter 
Automatic Defibrillator Implantation Trial (MADIT II) 
enrolled patients with a prior history of a myocardial 
infarction and an EF of less than 30 percent. Unlike the 
original study, the MADIT II did not require the presence 
of spontaneous or inducible arrhythmia or electrophysi-
ologic studies (Moss et al., 2002). The patients were ran-
domized to either conventional therapy or prophylactic 
ICD; however, the study was prematurely terminated 
after a follow-up of 20 months because the ICD sig-
nificantly reduced all-cause mortality (19.8 versus 14.2, 
P=0.016). Follow-up analysis revealed that the survival 
benefit was entirely due to a reduction in sudden death 
(3.8 versus 10 percent) (Greenberg et al., 2004). 
Unlike in MADIT I, where the benefit was evident after 
the first month of ICD use, in MADIT II divergence did 
not appear until after nine months. Moss and colleagues 
attributed this difference to the lower mortality rate in 
the conventional-therapy group in the MADIT II study, 
and the absence of the stringent criteria used in the 
original study, the lower EF eligibility, and the use of 
more optimal medical management (Moss et al., 2002). 
Subsequently, such results led to the FDA approval of ICD 
implantation for primary prevention. 
The Coronary Artery Bypass Graft (CABG) Patch Trial 
evaluated the role of ICD in reducing the overall long-
term mortality in patients undergoing surgical revas-
cularization for severe coronary heart disease, with EF 
below 36 percent, and abnormalities on signal-averaged 
electrocardiogram (Bigger, 1997). The trial randomized 
patients at the time of the CABG procedure to either 
implantation of an epicardial defibrillator or a control 
group. After a follow-up of 32 months, the study was 
terminated when no benefit was evident during interim 
analysis. 
Bigger and colleagues attempted to resolve the lack of 
significance in the CABG Patch Trial. They examined the 
cause of death in the trial, and demonstrated that only 
54 deaths (27%) occurred out of hospital, with majority 
of deaths occurring in the hospital prior to discharge 
early in the postoperative period. In the CABG Patch 
Trial, ICD therapy reduced arrhythmic death by 45 per-
cent without significant effect on nonarrhythmic deaths, 
and since 71 percent of the deaths were nonarrhythmic, 
total mortality was not significantly reduced (Bigger, 
1999). In addition, the CABG Patch Trial used ICDs with 
an epicardial-lead system which might be less effective 
(Domanski et al., 1999).
The Multicenter Unsustained Tachycardia Trial (MUSTT) 
(Buxton et al., 1999) evaluated the role of antiarrhythmic 
therapy guided by electrophysiologic testing (Buxton 
et al., 1999). Patients with inducible VT were randomly 
assigned to either no therapy or antiarrhythmic therapy 
guided by serial electrophysiological studies. Patients 
would receive a defibrillator only if one or more of the 
trial drugs were tried and were found to be unsuccessful. 
After five years, a significant benefit was demonstrated 
with electrophysiologically guided (EPG) therapy with 
25 percent of patients in the EPG guided therapy and 
32 percent of patient without antiarrhythmic therapy 
reaching primary end point of cardiac arrest or death 
from arrhythmia (RR 0.73; P=0.04) (Table 5). The five-
year estimates of overall mortality showed trends of 
42 and 48 percent, respectively (P=0.06). Nevertheless, 
the reduction in overall mortality and SCD in the EPG 
guided group were largely attributed to ICD therapy; 
at five years, SCD occurred in 9 percent of patients with 
EPG guidance and ICD therapy versus 37 percent of 
patients with EPG therapy without ICD (Table 5). Similar 
results were demonstrated for overall mortality, with 24 
percent and 55 percent, respectively. However, due to 
its atypical inclusion criteria, some have suggested that 
the MUSTT study may be better described as a test of an 
electrophysiologically guided treatment strategy since 
the investigators prescribed ICDs based on EPG studies 
and not in a randomized fashion (DiMarco, 2003).
The majority of patients evaluated in the studies of 
primary prevention trials included patients who had 
experienced a myocardial infarction (MI) more than six 
months prior to enrollment. Since the mortality rates 
remain high, and a significant cause of mortality post 
MI is attributed to arrhythmia, the Defibrillator in Acute 
Myocardial Infarction Trial (DINAMIT) set out to assess 
the benefit of prophylactic ICDs in this patient popula-
tion (Hohnloser et al., 2004). This study randomized 
patients within 40 days of a MI to ICD implantation with 
optimal medical therapy (OMT) and compared all-cause 
mortality to OMT alone.
The study enrolled patients with a history of recent MI, 
within 6 to 40 days, with EF of less than 35 percent and 
impaired cardiac autonomic function. After an aver-
age follow up of 30 months there was no difference in 
overall mortality between the two treatment groups 
(P=0.66). Although the study revealed a significant 
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reduction in SCD (P=0.009), this was offset by an increase 
in non-arrhythmic death (P=0.02). Therefore, it seems 
that ICD therapy changed the risk of death from arrhyth-
mic to non-arrhythmic causes. 
Non-Ischemic (Tables 6 and 7)
Although primary ischemic cardiomyopathy prevention 
trials had fueled a dramatic growth in the use of ICDs 
by the turn of the century, scarce data was available for 
benefits of ICD application in heart failure patients with 
non-ischemic cardiomyopathy (Josephson and Wellens, 
2004) (Tables 6 and 7).
The Cardiomyopathy Trial (CAT) was one of the first tri-
als to evaluate the role of ICD therapy in patients with 
non-ischemic cardiomyopathy (Bansch et al., 2002). It 
randomly assigned patients with recent onset dilated 
cardiomyopathy (DCM) of non-ischemic etiology and 
EF of less than 30 percent to either an ICD or a control 
group. The trial was terminated early after inclusion of 
only 104 patients because the all-cause mortality rate 
after one year was much lower than the expected 30 
percent in the control group. As such, no significant 
mortality benefit was evident after one, two, and four-
year follow-ups. Accordingly, the investigators argued 
that even if the study had continued to collect over 
1,300 patients, it would have less than 50 percent power 
Effect of EPG therapy
 No Treatment EPG guided Relative risk of 
  treatment event with EPG 
   therapy (95% CI) 
Death due to  32% 25% 0.73; (0.53-0.99);
arrhythmia    P=0.04
Overall Mortality 48% 42% 0.80; (0.64-1.01); 
   P=0.06
Effect of ICD therapy
 EPG without ICD EPG with ICD 
Death due to  37% 9% P<0.001
arrhythmia
Overall Mortality 55% 24% P<0.001
TABLE 5 I RESULTS OF THE MUSTT TRIAL
CI = confidence interval; EpG = Electrophysiologically guided; ICD = implantable cardioverter defibrillator; 
MUSTT = Multicenter Unsustained Tachycardia
Trial N Age Mean LVEF (%) Follow-ups Control
    (Months)  Therapy
CAT 104 52  24 66 ± 26  No ICD
AMIOVIRT 103 59 23 24 ± 16  Amiodarone
DEFINITE 458 58 21 29 ± 14  Medical Therapy 
SCD-HeFT 2521 60 25 45.5  Placebo
TABLE 6 I  PRIMARY PREVENTION TRIALS IN PATIENTS WITH 
 NON-ISCHEMIC CARDIOMYOPATHY 
AMIOvIRT = Amiodarone Versus Implantable Cardioverter-Defibrillator Randomized Trial; CAT = Cardiomyopathy 
Trial; DEFINITE = Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; ICD = implantable cardio-
verter defibrillator; LvEF = left ventricular ejection fraction; SCD-HeFT = Sudden Cardiac Death-Heart Failure Trial 
Plus-minus values are means ± standard deviation.
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to show the expected difference of six percent between 
the two groups. 
Of note, CAT was a multicenter study with a very poor 
enrollment rate. It took over six years to enroll 104 
patients among 15 centers combined. In addition, the 
number and clinical characteristics of screened yet not 
enrolled patients in the trial and their outcomes remain 
unknown. Moreover, the trial limited its inclusion to 
patients with recently diagnosed cardiomyopathy. 
Similarly, the Amiodarone Versus Implantable 
Cardioverter-Defibrillator Randomized Trial (AMIOVIRT) 
examined the impact of ICD therapy versus amiodarone 
in non-ischemic DCM patients with EF less than 35 per-
cent (Strickberger et al., 2003). However, unlike the pre-
vious studies which included only newly diagnosed DCM, 
AMIOVIRT included patients with established DCM. The 
study also included patients with asymptomatic non-sus-
tained VT as part of its inclusion criteria. However, the 
study was stopped prematurely due to a lack of benefit 
at one or three year follow-up. Similar to the CAT study, 
AMIOVIRT was hindered by its small sample size and 
mortality rates which fell well below their original esti-
mate. Hence, the AMIOVIRT authors argued that with 
the observed mortality rates, over 12,000 patients would 
have been required to achieve a power of 80 percent. 
However, others argue that the discrepancy between 
previously reported mortality rates and the remarkably 
low observed mortality rates in these two trials may be 
due to differences in patient selection and medication 
usage (Grimm, 2003).
The Defibrillators in Non-Ischemic Cardiomyopathy 
Treatment Evaluation (DEFINITE) randomized patients 
with non-ischemic DCM, an EF of less than 36 percent, 
and premature ventricular complexes or non-sustained 
VT (Kadish et al., 2004). It found a trend toward a reduc-
tion in mortality (P=0.08) and a significant benefit in 
SCD (P=0.006) with ICD compared to optimal medical 
therapy. The all cause mortality rate in the control group 
was 14.1 percent; however, only about one third of the 
deaths were due to sudden death, well below the origi-
nally anticipated 50 percent. Consequently, the trial was 
underpowered to demonstrate a significant difference 
in all cause mortality. The investigators attributed the 
low mortality rate to the fact that eighty-five percent 
of patients in the DEFINITE trial were treated with ACE 
inhibitors and beta-blockers, a higher compliance rate 
than previous trials (Moss et al., 1996; Moss et al., 2002). 
The lower than expected number of SCD due to arrhyth-
mia may have been due to the high use of beta-blockers 
and ACE inhibitors (Waagstein et al., 1997; Heidenreich 
et al., 1997; Poole-Wilson et al., 2003).
Recently, the Sudden Cardiac Death in Heart Failure 
Trial (SCD-HeFT), a large, multicenter, randomized trial 
of patients with either ischemic or non-ischemic heart 
failure, NYHA Class II or III, and EF less than 35 percent, 
compared the placebo, amiodarone, and single-lead 
ICD in addition to conventional therapy (Bardy et al., 
2005). After a five year follow up, the study revealed 
therapy with ICD significantly decreased the relative risk 
of death by 23 percent as compared to placebo, regard-
less of heart failure etiology (P=0.007). In addition, the 
sub-group analysis revealed that ICD therapy had a 
significant benefit in patients in NYHA class II, but not 
in NYHA class III heart failure. In contrast, amiodarone 
therapy had no benefit in patients in NYHA class II, and 
even decreased survival among patients in NYHA class III 
heart failure. 
In comparison to the AMIOVIRT and DEFINITE, which 
failed to exhibit a mortality benefit in patients with 
non-ischemic cardiomyopathy, this larger study did not 
require the presence of non-sustained VT as entry cri-
teria. In addition, although the mortality benefit was 
smaller than previous studies, the authors attribute this 
 Overall Mortality (%) Death Due to SCD (%)
Trial Control ICD P Control ICD P
CAT 31.4 26.0 0.554 N/A N/A N/A
AMIOVIRT 13.5 11.8 0.8 3.8 2.0 0.7
DEFINITE 14.1 7.9 0.08 6.1 1.3 0.006
SCD-HeFT 28 23 0.007 N/A N/A N/A
TABLE 7 I  PRIMARY PREVENTION TRIALS IN PATIENTS WITH NON-ISCHEMIC 
 CARDIOMYOPATHY AND EFFECT ON MORTALITY AND SCD
AMIOvIRT = Amiodarone Versus Implantable Cardioverter-Defibrillator Randomized Trial; CAT = Cardiomyopathy 
Trial; DEFINITE = Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; ICD = implantable cardioverter 
defibrillator; N/A = Data Not Available; SCD-HeFT = Sudden Cardiac Death-Heart Failure Trial. SCD = Sudden Cardiac 
Death. Plus-minus values are means ± standard deviation.
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CLASS I:
1.  Cardiac arrest due to VF or VT, not due to transient or reversible cause.
2.  Spontaneous sustained VT in association with structural heart disease. 
3.  Syncope of undetermined origin with clinically relevant, hemodynamically significant 
sustained VT or VF induced at electrophysiological study when drug therapy is ineffective 
not tolerated, or not preferred.
4.  Non-sustained VT with coronary artery disease, prior MI, LV dysfunction, and inducible 
VF or sustained VT at electrophysiological study that is not suppressible by a class I 
antiarrhythmic drug.
CLASS IIA:
1.  Patients with LVEF of 30 percent, at least one month post MI and three months post 
coronary revascularization surgery. 
CLASS IIB:
1.  Cardiac arrest presumed to be due to VF when electrophysiological testing is precluded 
by other medical conditions.
2.  Severe symptoms (eg, syncope) attributable to ventricular tachyarrhythmias in patients 
waiting cardiac transplantation.
3.  Familial or inherited conditions with a high risk for life-threatening ventricular 
tachyarrhythmias such as the long QT syndrome or hypertrophic cardiomyopathy.
4.  Nonsustained VT with coronary artery disease, prior MI, LV dysfunction, and inducible 
sustained VT or VF at electrophysiological study.
5.  Recurrent syncope of undetermined etiology in the presence of ventricular dysfunction 
and inducible ventricular arrhythmias when other causes of syncope have been excluded.
6.  Syncope of unexplained etiology or family history of unexplained sudden cardiac death in 
association with typical or atypical right bundle-branch block and ST-segment elevations 
(Brugada syndrome).
7.  Syncope in patients with advanced structural heart disease in which thorough invasive 
and noninvasive investigation has failed to define a cause.
CLASS III:
1.  Syncope of undetermined cause in a patient without inducible ventricular 
tachyarrhythmias and without structural heart disease.
2.  Incessant ventricular tachyarrhythmias.
3.  Ventricular tachyarrhythmias arising from rhythm disturbances that are amenable to 
surgical or catheter ablation.
4.  Ventricular tachyarrhythmias due to a transient or reversible disorder when correction of 
the disorder is considered feasible and likely to substantially reduce the risk of recurrent 
arrhythmia.
5.  Significant psychiatric illnesses that may be aggravated by device implantation or may 
preclude systematic follow-up.
6.  Terminal illnesses with projected life expectancy more than 6 months.
7.  Patients with coronary artery disease, left ventricular dysfunctional, and prolonged QRS 
duration without spontaneous or inducible-ventricular tachycardia undergoing coronary 
artery bypass surgery.
8.  Patients with class IV heart failure who are not candidates for cardiac transplantation.
TABLE 8  INDICATIONS FOR IMpLANTABLE CARDIOvERTER DEFIBRILLATORS THERApy*
EF = Ejection fraction, LvEF = Left Ventricular Ejection Fraction, MI = Myocardial Infarction, vF = Ventricular Fibrillation, 
vT = Ventricular Tachycardia 
*Adapted and modified from Gregoratos et al., 2002. 
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discrepancy to the higher compliance with optimal medi-
cal therapy. Nevertheless, this study is by far the largest 
trial to date to that assesses the application of ICD thera-
py in primary prevention for patients with non-ischemic 
cardiomyopathy.
CONCLUSION
There have been dramatic advances in the treatment 
of patients with ventricular arrhythmias. Over the last 
quarter of century, ICD therapy has proven to be a highly 
effective treatment in reducing the risk of arrhythmic 
death when used as either a primary or secondary pre-
ventative measure. There seems to be little doubt that 
ICD therapy should be routinely considered in some 
patients, such as those with advanced ischemic cardio-
myopathy who are resuscitated after ventricular fibrilla-
tion. However the debate for the role of ICD in primary 
prevention is ongoing. As indications for ICD therapy 
begin to expand rapidly, it is clear that stringent proven 
methods for risk stratification are vital. 
In 2002, the American College of Cardiology updated 
its recommendations in accordance with published trials 
(Table 8) (Greegoratos et al., 2002). However, in light of 
new data from recent trials that have demonstrated a 
role for ICD therapy in selected patients with non-isch-
emic cardiomyopathy, it is clear that current recommen-
dations have to be revisited, revised, and made more 
comprehensive to include patients with non-ischemic 
cardiomyopathy with poor left ventricular function. 
However, additional research is required to further iden-
tify appropriate patient characteristics.
Also in light of the new data from latest trials, the Center 
for Medicare and Medicaid Services expanded its previ-
ous 2003 guidelines, which were based on the MADIT II 
criteria, to include prophylactic use of ICD in high risk 
patients with ischemic or non-ischemic cardiomyopathy 
and EF of less than 30 percent. If clinical trials prove to 
be right, such expansion will enable an even greater 
number of individuals with heart failure to benefit from 
ICD therapy. Furthermore, recent trials that included car-
diac resynchronization therapy in conjunction with ICD 
therapy in patients with severe heart failure have had 
promising results (Bristow et al., 2004; Young et al., 2003; 
Higgins et al., 2003). 
Further large randomized controlled trials are needed to 
fully recognize the potential of such therapies. Although 
it is clear that ICDs can convert malignant ventricular 
arrhythmias to sinus rhythm, such benefits are associated 
with a large cost to society, as each device implantation 
and follow-up would add billions of dollars to Medicare 
costs alone (Morgan, 2002; Owen et al., 2002; Weiss and 
Saynina, 2002; Exner et al., 2001). A discussion of cost-
effectiveness analysis and affect on quality of life were 
beyond the scope of this review. However, these consid-
erations are vital and continued debate and research will 
determine how far individuals and society are willing to 
implement such therapies. 
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